Health Technology · Pharmaceuticals: Major · NSE: LASA · data 2026-10-09

Lasa Supergenerics Ltd.

Health check: Weak (1.2/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹5.32

Market cap

₹27 cr

P/E

—

P/B

—

ROE

-51.1%

ROCE

-27.0%

Debt / equity

0.2

Dividend yield

0.00%

1-year return

-53.8%

52-week high

₹12.48

52-week low

₹5.32

Operating margin

-224.5%

Growth

Revenue (last 12 months)	₹6 cr
Net profit (last 12 months)	₹-17 cr
Sales growth, 3 years (yearly)	-42.1%
Profit growth, 3 years (yearly)	—

Chart patterns

Double top — breakdown (key level ₹6.66)

Similar companies

Mangalam Drugs & Organics Ltd. (MANGALAM) · Biofil Chemicals & Pharmaceuticals Ltd. (BIOFILCHEM) · Medicamen Organics Ltd. (MEDIORG) · Medi-Caps Ltd. (MEDICAPQ) · Sunrest Lifescience Limited (SUNREST)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open LASA in NSE Scanner →